Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 10, 2015, 81 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $2,123.51 to $171,339,525.00.

Highlighted Stocks Traded by Insiders:

CareFusion (CFN) - FREE Research Report

Wygant Jonathan, who is SVP, Chief Accounting Officer at CareFusion, sold 1,700 shares at $59.79 on Feb. 10, 2015. Following this transaction, the SVP, Chief Accounting Officer owned 2,181 shares meaning that the stake was reduced by 43.8% with the 1,700-share transaction.

The shares most recently traded at $59.74, down $0.05, or 0.08% since the insider transaction. Historical insider transactions for CareFusion go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 1,000
  • 24-Week # shares sold: 12,000

The average volume for CareFusion has been 2.1 million shares per day over the past 30 days. CareFusion has a market cap of $12.2 billion and is part of the health care sector and health services industry. Shares are up 0.61% year-to-date as of the close of trading on Tuesday.

CareFusion Corporation, a medical technology company, provides various healthcare products and services. It offers product lines in the areas of medication management, infection prevention, operating room effectiveness, and respiratory care. The company has a P/E ratio of 25.4. Currently, there are no analysts who rate CareFusion a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CFN - FREE

TheStreet Quant Ratings

rates CareFusion as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full

CareFusion Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Versar (VSR) - FREE Research Report

Otten Anthony L., who is Chief Executive Officer at Versar, bought 1,000 shares at $3.44 on Feb. 10, 2015. Following this transaction, the Chief Executive Officer owned 123,589 shares meaning that the stake was boosted by 0.82% with the 1,000-share transaction.

The shares most recently traded at $3.39, down $0.05, or 1.47% since the insider transaction. Historical insider transactions for Versar go as follows:

  • 4-Week # shares bought: 3,000
  • 12-Week # shares bought: 3,000
  • 24-Week # shares bought: 11,800

The average volume for Versar has been 150,200 shares per day over the past 30 days. Versar has a market cap of $34.3 million and is part of the services sector and diversified services industry. Shares are up 9.49% year-to-date as of the close of trading on Tuesday.

Versar, Inc. operates as a project management company in the United States and internationally. The company operates through three segments: Engineering and Construction Management, Environmental Services, and Professional Services. Currently, there are no analysts who rate Versar a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VSR - FREE

TheStreet Quant Ratings

rates Versar as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full

Versar Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cavium (CAVM) - FREE Research Report

Jain Anil Kumar, who is Corporate VP, IC Engineering at Cavium, sold 12,881 shares at $59.00 on Feb. 10, 2015. Following this transaction, the Corporate VP, IC Engineering owned 51,307 shares meaning that the stake was reduced by 20.07% with the 12,881-share transaction.

The shares most recently traded at $60.93, up $1.93, or 3.17% since the insider transaction. Historical insider transactions for Cavium go as follows:

  • 4-Week # shares sold: 1,946
  • 12-Week # shares sold: 1,946
  • 24-Week # shares sold: 1,946

The average volume for Cavium has been 687,500 shares per day over the past 30 days. Cavium has a market cap of $3.1 billion and is part of the technology sector and electronics industry. Shares are down 0.95% year-to-date as of the close of trading on Tuesday.

Cavium, Inc. designs, develops, and markets semiconductor processors for intelligent and secure networks. The company operates through Semiconductor Products, and Software and Services segments. Currently, there are 12 analysts who rate Cavium a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CAVM - FREE

TheStreet Quant Ratings

rates Cavium as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full

Cavium Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null